ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1643

Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol

Megan E. B. Clowse1, Douglas C. Wolf2, Christian Stach3, Gordana Kosutic4, Susan Williams4, Ido Terpstra5 and Uma Mahadevan6, 1Rheumatology, Duke University Medical Center, Durham, NC, 2Atlanta Gastroenterology Associates, Atlanta, GA, 3UCB Pharma, Monheim, Germany, 4UCB Pharma, Raleigh, NC, 5UCB Pharma, Brussels, Belgium, 6University of California, San Francisco, San Francisco, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, certolizumab pegol, pregnancy and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-TNF approved in the US for the treatment of Crohn’s disease (CD) and rheumatoid arthritis (RA). Pre-clinical and clinical data suggest a lack of active neonatal Fc receptor-dependent placental transfer of CZP [1, 2]. There are few reports of pregnancy outcomes following exposure to CZP to date.  This work provides additional information regarding the primary pregnancy outcomes in women exposed to CZP.

Methods:

The global CZP safety database was searched for all medically confirmed cases of pregnancy through March 6, 2012. The proportion of live births, spontaneous miscarriages, and elective terminations for women directly exposed to CZP before or during confirmed pregnancy were compared to those expected for the general US population of pregnant women.

Results:

Of 294 reported pregnancy events, 152 had known outcomes, 89 had unknown outcomes and 53 were ongoing. Of the 152 events with known outcomes, 139 were cases in which the mother had direct exposure to CZP, with 57 from the clinical trial program and 82 from post-marketing reports. The remaining 13 were cases with the father exposed to CZP resulting in 10 live births, 2 miscarriages and 1 elective termination. Of the 139 direct exposure cases with known outcomes, the underlying conditions were CD (N=107), RA (N=17) and healthy subjects (N=2) with 13 cases classified as other or having missing data. 91 of 139 cases were from the US. 103 of 139 pregnancies resulted in live births (see table) and the median gestational age was 38.3 weeks (data available for 40 births). 21 pregnancies ended in spontaneous miscarriage. 15 pregnancies resulted in elective termination. These results are similar to those reported in the general population in the US (see table). In 103 live births there were 2 reported cases of congenital disorder (Rate in the US general population is 3% [4]); 1 baby had mild, unilateral hydronephrosis on antenatal ultrasound and was described as healthy upon birth. The other baby had vesicoureteric reflux.

Conclusion:

Currently available data from 139 pregnant women exposed to CZP, report outcomes consistent with the US National Vital Statistics data. Additional data from larger numbers of pregnant women exposed to CZP are required to validate acceptable safety and tolerability of CZP in pregnancy.

References:

1. Wakefield I et al. Toxicol Sci 2011;122(1):170-6. 2. Wolf D and Mahadevan U. Arthritis Rheum 2010;62 Suppl 10 :718. 3. Ventura SJ et al. Natl Vital Stat Rep. 2008;56(15):1-25, 28. 4. CDC MMWR 2008; 57(01);1-5


Disclosure:

M. E. B. Clowse,

UCB,

5;

D. C. Wolf,

UCB,

5;

C. Stach,

UCB,

3,

UCB,

1;

G. Kosutic,

UCB,

3,

UCB,

1;

S. Williams,

UCB,

3;

I. Terpstra,

UCB,

1,

UCB,

3;

U. Mahadevan,

UCB,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/outcomes-of-pregnancy-in-subjects-exposed-to-certolizumab-pegol/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology